natgillin/translations-raw huggingface dataset:
What are the risks associated with Iclusig? 
Mis riskid Iclusigiga kaasnevad?
The most common serious side effects with Iclusig (which may affect more than 2 in 100 people) are pneumonia (infection of the lungs), pancreatitis (inflammation of the pancreas), pyrexia (fever), abdominal pain (stomach ache), myocardial infarction (heart attack), atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), peripheral arterial occlusive disease (problem with blood flow in the arteries), anaemia (low red blood cell counts), angina pectoris (pains to the chest, jaw and back due to problems with blood flow to the heart), decreased blood levels of platelets (components that help the blood to clot), febrile neutropenia (low white blood cell counts with fever), hypertension (high blood pressure), coronary artery disease (heart disease caused by the obstruction of the blood vessels that supply the heart muscle), cardiac failure (when the heart does not work as well as it should), cerebrovascular accident (stroke), sepsis (blood poisoning), cellulitis (inflammation of the deep skin tissue), acute kidney injury (kidney damage), urinary tract infection (infection of the structures that carry urine) and increased levels of lipase (an enzyme). 
Iclusigi kõige sagedamad rasked kõrvalnähud (võivad esineda rohkem kui 2 inimesel 100st) on kopsupõletik, pankreatiit (kõhunäärmepõletik), palavik, kõhuvalu, südameinfarkt, kodade virvendus (südamekodade korrapäratu kiire kokkutõmbumine), perifeersete arterite oklusiivne haigus (arteriverevoolu teatud probleem), aneemia (erütrotsüütide ehk vere punaliblede vähesus), stenokardia (südamelihase verevarustuse probleemidest tingitud valu rindkeres, lõuas ja seljas), trombotsüütide (vereliistakute ehk vere hüübimises osalevate vererakkude) vähesus, febriilne neutropeenia (neutrofiilide ehk teatud valgeliblede vähesus koos palavikuga), hüpertensioon (kõrge vererõhk), südame isheemiatõbi (südamelihast verega varustavate arterite ahenemisest tingitud südamehaigus), südamepuudulikkus (süda ei pumpa organismi piisavalt verd),insult, septitseemia (nakkusveresus), tselluliit (naha süvakudede põletik), äge neerupuudulikkus (neerukahjustus), kuseteede infektsioon (nakkus) ja lipaasi (teatud ensüüm) aktiivsuse suurenemine veres.
Further information on the orphan designations can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (CML; ALL). 
Lisateave harvikravimiks nimetatud ravimi kohta on leitav: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (CML; ALL).
The doctor should consider stopping treatment if the level of white cells in the blood does not return to normal within three months. 
Ravi lõpetamist peab kaalutlema, kui leukotsüütide sisaldus ei normaliseeru kolme kuu jooksul.
The company that markets Iclusig will provide educational material for all doctors who are expected to prescribe this medicine highlighting important risks for which monitoring and dose adjustments are recommended. 
Iclusigi turustaja varustab kõik ravimit eeldatavalt määravad arstid teabematerjaliga, mis rõhutab olulisi riske, mille korral soovitatakse jälgimist ja annuste kohandamist.
Also, the company will conduct a study in order to determine the best starting dose of Iclusig and to assess the safety and effectiveness of Iclusig following dose reduction in patients with chronic phase CML who achieve major cytogenetic response. 
Lisaks korraldab ettevõte uuringu, et määrata Iclusigi sobivaim algannus ning hinnata Iclusigi ohutust ja efektiivsust pärast annuse vähendamist kroonilises faasis CML-iga patsientidel, kellel tekib oluline tsütogeneetiline ravivastus.
If a patient develops certain severe side effects, the doctor may decide to reduce subsequent doses or delay or stop treatment. 
Kui patsiendil tekivad teatud rasked kõrvalnähud, võib arst otsustada annust vähendada või ravi edasi lükata või lõpetada.
The results of the study showed that treatment with Iclusig led to clinically relevant responses in all groups of patients: 
Uuringu tulemused tõendasid, et Iclusig-ravi tekitas kõigis patsiendirühmades kliiniliselt olulise ravivastuse:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Iclusig have also been included in the summary of product characteristics and the package leaflet. 
Iclusigi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
By blocking Bcr-Abl, Iclusig helps to control the growth and spread of leukaemia cells. 
Kinaasi Bcr-Abl blokeerides aitab Iclusig piirata leukeemiarakkude kasvu ja levimist.
Ph+ means that some of the patient's genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome that leads to the development of leukaemia. 
Ph+ tähendab, et patsiendi osa geenide ümberkorralduse tõttu on tekkinud eriline kromosoom, mida nimetatakse Philadelphia kromosoomiks ja mis viib leukeemia tekkele.
It is used to treat adults with the following types of leukaemia (cancer of the white blood cells): 
Seda kasutatakse täiskasvanutel järgmiste leukeemia (leukotsüütide ehk vere valgeliblede vähi) vormide raviks:
Other information about Iclusig 
Muu teave Iclusigi kohta
These diseases are rare, and Iclusig was designated an ‘orphan medicine' (a medicine used in rare diseases) on 2 February 2010. 
Need haigused esinevad harva ja Iclusig nimetati 2. veebruaril 2010 harvikravimiks.
• acute lymphoblastic leukaemia (ALL) in patients who are ‘Philadelphia-chromosome positive' (Ph+). 
• akuutne lümfoblastne leukeemia (ALL) Philadelphia kromosoomiga (Ph+) patsientidel.
In the study, Iclusig was not compared with another treatment. 
Uuringus ei võrreldud Iclusigi ühegi muu raviviisiga.
For more information about using Iclusig, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Iclusigi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
What benefits of Iclusig have been shown in studies? 
Milles seisneb uuringute põhjal Iclusigi kasulikkus?
The Philadelphia-chromosome is found in some ALL patients and is present in most patients with CML. 
Philadelphia kromosoom esineb osal ALL-iga patsientidel ja enamikul CML-iga patsientidest.
Regarding its safety, the side effects with Iclusig were largely similar to those of other tyrosine kinase inhibitors and mostly manageable with dose reduction or dose delay. 
Ohutuse osas sarnanevad Iclusigi kõrvalnähud üldiselt teiste türosiinkinaasiinhibiitorite omadega ja neid saab piirata annust vähendades või edasi lükates.
For the full list of side effects and restrictions with Iclusig, see the package leaflet. 
Iclusigi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
Side effects reported with Iclusig are carefully evaluated and any necessary action taken to protect patients. 
Iclusigi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
How does Iclusig work? 
Kuidas Iclusig toimib?
The risk of problems (including heart attacks and strokes) resulting from blood clots or blockages in arteries or veins could be reduced by checking for and treating contributory conditions such as high blood pressure and raised cholesterol both before and during treatment. 
Arteri- või veenitrombidest või -ummistusest tekkivate probleemide (sh südameinfarkti ja insuldi) riski saab vähendada, kontrollides ja ravides soodustavaid tegureid, näiteks kõrget vererõhku ja kõrgenenud kolesteroolisisaldust nii enne ravi kui ka ravi ajal.
Iclusig was shown to be an effective treatment for those patients with CML or Ph+ ALL who have limited treatment options. 
Tõendatud on Iclusig-ravi efektiivsus nendel CML-iga või Ph+ ALL-iga patsientidel, kelle ravivõimalused on piiratud.
Iclusig is used in patients who cannot tolerate or do not respond to dasatinib (patients with CML or ALL) or nilotinib (patients with CML), which are other cancer medicines of the same class, and for whom subsequent treatment with imatinib (a third such medicine) is not considered appropriate. 
Iclusigi kasutatakse patsientidel, kellel esineb muude sama ravimiklassi vähiravimite (CML-iga või ALLiga patsientidel) dasatiniibi või (CML-iga patsientidel) nilotiniibi talumatus või resistentsus ja kelle puhul ei peeta edasist ravi imatiniibiga (kolmas samalaadne ravim) sobivaks.
The response to treatment was assessed by measuring the proportion of patients who had a ‘major haematological response' (when the number of white blood cells returns to normal or there is no evidence of leukaemia) or a ‘major cytogenetic response' (when the proportion of white blood cells containing the Philadelphia chromosome falls to below 35%). 
Ravivastust hinnati nende patsientide protsendi järgi, kellel tekkis oluline hematoloogiline ravivastus (leukotsüütide sisaldus veres normaliseerus või leukeemianähud kadusid) või oluline tsütogeneetiline ravivastus (Philadelphia kromosoomiga leukotsüütide protsent vähenes alla 35%).
It is also used in patients who have a genetic mutation called ‘T315I mutation' which makes them resistant to treatment with imatinib, dasatinib or nilotinib. 
Ravimit kasutatakse ka patsientidel, kellel esineb T315I-geenimutatsioon, mis muudab nad imatiniibi, dasatiniibi ja nilotiniibiga toimuva ravi suhtes resistentseks.
Arterial occlusive adverse events (clots or blockages in the arteries) occurred in 25% of patients, with serious adverse events occurring in 20% of patients. 
Arteriummistustega seotud kõrvalnähte (arterite trombe või ummistusi) esines 25% patsientidest, raskel kujul 20% patsientidest.
Iclusig has been investigated in one main study involving 449 patients with CML or Ph+ ALL and who were intolerant or resistant to treatment with dasatinib or nilotinib, or had the T315I mutation. 
Iclusigi uuriti ühes põhiuuringus, milles osales 449 CML-iga või Ph+ ALL-iga patsienti, kes ei talunud ravi dasatiniibi või nilotiniibiga või olid nende ravimite suhtes resistentsed või kellel oli mutatsioon T315I.
• chronic myeloid leukaemia (CML) in its different stages known as chronic, accelerated and blast phases; 
• kroonilises, aktseleratsiooni- või blastses faasis krooniline müeloidleukeemia (CML);
Ponatinib acts by blocking a tyrosine kinase called Bcr-Abl. 
Ponatiniib toimib türosiinkinaasi Bcr-Abl blokeerides.
Iclusig is a cancer medicine that contains the active substance ponatinib. 
Iclusig on vähiravim, mis sisaldab toimeainena ponatiniibi.
Iclusig can only be obtained with a prescription and treatment should be started by a doctor who is experienced in the diagnosis and treatment of leukaemia. 
Iclusig on retseptiravim ja ravi sellega peab alustama leukeemia diagnoosimises ja ravis kogenud arst.
Venous thromboembolic reactions (problems due to blood clots in the veins) occurred in 6% of patients. 
Venoosse trombemboolia (veenitrombidest põhjustatud probleemid) juhte esines 6% patsientidest.
An overview of Iclusig and why it is authorised in the EU 
Ülevaade ravimist Iclusig ja ELis müügiloa väljastamise põhjendus
• among the patients with Ph+ ALL, around 41% (13 out of 32) had a major haematological response. 
• Ph+ ALL-iga patsientidest oli olulise hematoloogilise ravivastusega 41% (13 patsienti 32st).
Serious venous occlusive adverse events (clots or blockages in the veins) occurred in 5% of patients. 
Veeniummistustega (veenide trombid või ummistused) seotud raskeid kõrvalnähte esines 5% patsientidest.
How is Iclusig used? 
Kuidas Iclusigi kasutatakse?
These compounds act by blocking enzymes known as tyrosine kinases. 
Need ained blokeerivad ensüüme türosiinkinaase.
The active substance in Iclusig, ponatinib, belongs to a group of medicines called ‘tyrosine kinase inhibitors'. 
Iclusigi toimeaine ponatiniib kuulub türosiinkinaasiinhibiitorite ravimirühma.
Iclusig can lead to clots or blockages in arteries and veins and patients should have the condition of their heart and circulation considered before starting and during treatment, and be treated appropriately for any problems. 
Iclusig võib põhjustada veresoontes trombe ja ummistusi, mille tõttu tuleb patsientide südameveresoonkonna seisundit kontrollida enne ravi ja ravi ajal.
The dose may need to be reduced or interrupted if the patient experiences certain side effects; it should be interrupted immediately if a blockage develops in an artery or vein. 
Teatud kõrvalnähtude esinemisel võib olla vaja annust vähendada või ravi katkestada; veeni või arteri ummistumisel tuleb ravi otsekohe katkestada.
• among the patients with CML in the chronic phase, around 54% (144 out of 267) had a major cytogenetic response; 
• kroonilises faasis CML-iga patsientidest oli olulise tsütogeneetilise ravivastusega 54%
• among the patients with CML in the accelerated phase, around 58% (48 out of 83) had a major haematological response; 
• aktseleratsioonifaasis CML-iga patsientidest oli olulise hematoloogilise ravivastusega ligikaudu 58%
• among the patients with CML in the blast phase, around 31% (19 out of 62) had a major haematological response; 
• blastses faasis CML-iga patsientidest oli olulise hematoloogilise ravivastusega 31% (19 patsienti
However, it was important to ensure that the pass limits of the potency test do not drift from the original. 
Siiski on oluline tagada, et potentstesti läbimise piirid ei kalduks algsetest väärtustest kõrvale.
In addition, a more robust test for potency should be applied to the product in the future. 
Lisaks sellele peaks edaspidi ravimi hindamisel rakendama tõhusamat potentstesti.
The CVMP concluded that, based on all available data, there was no concern regarding safety or efficacy for the product. 
Tuginedes olemasolevatele andmetele otsustas veterinaarravimite komitee, et ravimi ohutuse ega tõhususe osas probleeme ei ole.
The Marketing Authorisation(s) should be varied to reduce the variability of the serological potency test in mice by appropriate measures such as the replacement of the use of a reference vaccine in the serological potency test in mice with the use of reference serum. 
Müügiluba tuleb muuta, et vähendada hiirte seroloogilise potentstesti muutlikkust asjakohaste näitajateni, näiteks asendades võrdlusvaktsiini kasutamise hiirte seroloogilises potentstestis võrdlusseerumi kasutamisega.
The CVMP, therefore, recommended a variation of the Marketing Authorisation. 
Seetõttu soovitab veterinaarravimite komitee müügiluba muuta.
The referral deals with the issue that in the opinion of France equivalence between the reference vaccine batch for the erysipelas batch potency test validated in the original dossier and the new reference vaccine batches was not shown for these 2 batches and that consequently the CVMP needed to consider whether to vary, withdraw or suspend the marketing authorisation. 
2. tüübi teisendi hindamise ajal muutmaks hiirte potentstesti, et viia see vastavusse erüsiipeli vaktsiinide Ph.Eur monograafia täiendatud versiooniga, aktsepteeriti võrdlusvaktsiinina vaktsiinipartiid nr 8500 ning seetõttu tuleb tunnistada, et nii see partii kui ka sellest varasemad partiid vastavad mõlema ravimi müügiloa tingimustele.
London, June 2008 EMEA/532233/2007- Rev.1 
Tel: +34 91 5981343 Fax: +34 91 5972434 Email: rodrigv2@fdah.com
COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) 
Fort Dodge Animal Health SpA
OPINION FOLLOWING AN ARTICLE 40 REFERRAL FOR SUVAXYN ERY 
Email: lastrag@fdah.com
European Medicines Agency Veterinary Medicines and Inspections 
Animal species
Suvaxyn Ery is indicated for the active immunisation of pigs (gilts and sows) to reduce clinical signs caused by Erysipelothrix rhusiopathiae infections, serotype 2 and serotype 1. 
Rua Dr. António Loureiro Borges, nº2, ArquiparqueMiraflores, 1495-131 Algés
France notified the EMEA on 11 July 2006 of a Referral under Article 40 of Council Directive 2001/82/EC, as amended, in relation to Suvaxyn Ery. 
Käesolevas esildises sisalduvad võrdlusvaktsiini muudatused on seotud partii nr 8500 asendamisega partiiga nr 9097 ning partii nr 9097 asendamisega partiiga nr 9861.
This reduces bone loss. 
See vähendab luukoe hävimist,
Further information on Zoledronic Acid Accord can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/zoledronic-acid-accord. 
Lisateave ravimi Zoledronic Acid Accord kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/zoledronic-acid-accord.
The European Medicines Agency concluded that, in accordance with EU requirements, Zoledronic Acid Accord has been shown to have comparable quality and to be comparable to Zometa. 
Euroopa Ravimiamet järeldas, et vastavalt ELi nõuetele on tõendatud ravimi Zoledronic Acid Accord võrreldav kvaliteet ja sarnane toime ravimiga Zometa.
Zoledronic Acid Accord received a marketing authorisation valid throughout the EU on 16 January 
Zoledronic Acid Accord on saanud müügiloa, mis kehtib kogu ELis, 16. jaanuaril 2014.
What measures are being taken to ensure the safe and effective use of Zoledronic Acid Accord? 
Mis meetmed võetakse, et tagada ravimi Zoledronic Acid Accord ohutu ja efektiivne kasutamine?
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Zometa, and do not need to be repeated for Zoledronic Acid Accord. 
Võrdlusravimiga Zometa on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Zoledronic Acid Accord korrata.
Osteonecrosis of the jaw is a condition affecting the bones of the jaw, which could lead to pain, sores in the mouth or loose teeth. 
Osteonekroos on lõualuu kahjustus, mis võib tekitada valu, suuhaavandeid või hammaste logisemist.
This means that Zoledronic Acid Accord contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Zometa. 
See tähendab, et Zoledronic Acid Accord sisaldab sama toimeainet ja toimib samamoodi nagu võrdlusravim Zometa, millel juba on Euroopa Liidus müügiluba.
Side effects reported with Zoledronic Acid Accord are carefully evaluated and any necessary action taken to protect patients. 
Ravimi Zoledronic Acid Accord kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zoledronic Acid Accord have also been included in the summary of product characteristics and the package leaflet. 
Ravimi Zoledronic Acid Accord ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
For more information about using Zoledronic Acid Accord, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet ravimi Zoledronic Acid Accord kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
The usual dose is one infusion of 4 mg over at least 15 minutes. 
Ravimi Zoledronic Acid Accord tavaannus on 4 mg, mida manustatakse vähemalt 15 minutit kestva ühekordse infusioonina.
As for all medicines, data on the use of Zoledronic Acid Accord are continuously monitored. 
Nagu kõigi ravimite puhul, teostatakse ravimi Zoledronic Acid Accord kasutamise kohta pidevat järelevalvet.
Zoledronic Acid Accord can only be obtained with a prescription and must only be prescribed and given by a healthcare professional who has experience in the use of this type of medicine given into a vein. 
Zoledronic Acid Accord on retseptiravim ja seda tohib patsiendile määrata ja manustada üksnes seda tüüpi veenisiseste ravimite kasutamises kogenud tervishoiutöötaja.
The company that markets Zoledronic Acid Accord will provide a card to inform patients receiving Zoledronic Acid Accord about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they get symptoms. 
Turustaja varustab ravimit Zoledronic Acid Accord kasutavad patsiendid teabekaardiga, milles neid teavitatakse lõualuu osteonekroosi riskist ning soovitatakse neil sümptomite tekkimisel pöörduda arsti poole.
Therefore, the Agency's view was that, as for Zometa, the benefit outweighs the identified risk and it can be authorised for use in the EU. 
Seetõttu oli amet arvamusel, et nagu ka Zometa korral, ületab ravimi Zoledronic Acid Accord kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
Because Zoledronic Acid Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicines'. 
Et Zoledronic Acid Accord on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimitel.
As for every medicine, the company provided studies on the quality of Zoledronic Acid Accord. 
Nagu iga ravimi korral, esitas ettevõte ravimi Zoledronic Acid Accord kvaliteedi uuringud.
Zoledronic Acid Accord is a medicine used to prevent bone complications in adults with advanced cancer that is affecting the bone. 
Ravimit Zoledronic Acid Accord kasutatakse luutüsistuste ennetamiseks täiskasvanud patsientidel, kellel on kaugelearenenud vähk, mis kahjustab luukude.
Zoledronic Acid Accord can also be used to treat hypercalcaemia caused by tumours. 
Ravimit Zoledronic Acid Accord tohib kasutada ka kasvajast põhjustatud hüperkaltseemia raviks.
What is Zoledronic Acid Accord and what is it used for? 
Mis on Zoledronic Acid Accord ja milleks seda kasutatakse?
The medicine is given as an infusion (drip) into a vein. 
Ravimit manustatakse veeniinfusioonina.
By preventing the breakdown of bones, Zoledronic Acid Accord also helps to reduce the amount of calcium released into the blood. 
Luukoe lagunemist peatades aitab Zoledronic Acid Accord vähendada verre eralduva kaltsiumi kogust.
Zoledronic Acid Accord (zoledronic acid) 
Zoledronic Acid Accord (soledroonhape)
There was no need for ‘bioequivalence' studies to investigate whether Zoledronic Acid Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. 
Ravimi bioekvivalentsust, st kas Zoledronic Acid Accord imendub organismis samamoodi nagu võrdlusravim, et saavutada toimeaine sarnane sisaldus veres, ei olnud vaja uurida.
The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases. 
muutes luud murdudele vastupidavamaks, mis aitab ennetada luumurdude teket luumetastaasidega vähipatsientidel.
An overview of Zoledronic Acid Accord and why it is authorised in the EU 
Ülevaade ravimist Zoledronic Acid Accord ja ELis müügiloa väljastamise põhjendus
Zoledronic Acid Accord contains the active substance zoledronic acid and is a ‘generic medicine'. 
Ravim Zoledronic Acid Accord sisaldab toimeainena soledroonhapet ja on geneeriline ravim.
When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderately reduced kidney function. 
Kui ravimit kasutatakse luutüsistuste ennetamiseks, tohib infusiooni korrata iga 3-4 nädala tagant ning patsiendid peavad lisaks võtma kaltsiumi ja D-vitamiini.
This is because Zoledronic Acid Accord is given by infusion into a vein, so the active substance is delivered straight into the bloodstream. 
Seda ei olnud vaja, sest ravimit Zoledronic Acid Accord manustatakse veeniinfusioonina, mille abil satub toimeaine otse vereringesse.
Other information about Zoledronic Acid Accord 
Muu teave ravimi Zoledronic Acid Accord kohta
The active substance in Zoledronic Acid Accord, zoledronic acid, is a bisphosphonate. 
Ravimi Zoledronic Acid Accord toimeaine soledroonhape on bisfosfonaat.
How is Zoledronic Acid Accord used? 
Kuidas ravimit Zoledronic Acid Accord kasutatakse?
How does Zoledronic Acid Accord work? 
Kuidas Zoledronic Acid Accord toimib?
How has Zoledronic Acid Accord been studied? 
Kuidas ravimit Zoledronic Acid Accord uuriti?